Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical ...(technology and is underinternational dev...),Health

Date:9/26/2007

technology and is under international development for the management of post-operative pain following moderate/major abdominal, gynecological, thoracic, and orthopedic surgeries. Post-operative pain is typically controlled with narcotic analgesics such as morphine, but systemic administration of these drugs can result in unfavorable side effects including suppression of breathing, sedation, nausea and vomiting; and can also affect patient recovery. Innocoll's BUPIVACAINE SURGICAL IMPLANT is intended to provide pain control directly at the surgical site and thus reduce the level of additional analgesia required following surgery. The collagen matrix naturally biodegrades over a few days and the bupivacaine is released to provide local analgesia for up to 96 hours post-operatively. A key feature of Innocoll's product is the ability to implant it directly into the surgical cavity and at different layers within the wound, such as across the peritoneum incision and directly below the skin incision, which enables localized treatment of both the incisional and deep, visceral pain components in tandem.

The results of an initial clinical study performed at Wexham Park Hospital, Slough, UK, in patients undergoing hysterectomy surgery were particularly encouraging, showing evidence of sustained, post-operative analgesia for approximately 96 hours. Innocoll filed an IND in March 2007 and intends to conduct a series of phase 2, multi-centered, controlled clinical trials in a variety of soft tissue and orthopedic surgical models; including hysterectomy, herniorrhaphy, open gastrointestinal surgery and anterior cruciate ligament (ACL) repair. BUPIVACAINE SURGICAL IMPLANT is believed to offer broad utility across a variety of surgical disciplines, as reflected in independent market research recently performed by L.E.K. Consulting which expects the product to achieve peak US sales nearing US$310 million.

About CollaRx(R) Bupivacaine Topical

CollaRx BUPIVACAINE TOP
'/>"/>

SOURCE Innocoll, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer